BACKGROUND: The effect of protein-based meningococcal vaccines on prevention of nasopharyngeal colonization has been difficult to investigate experimentally because a reliable animal colonization model did not exist. METHODS: Human CEACAM1 transgenic mice, which can be colonized by meningococci, were immunized IP with one of two meningococcal native outer membrane vesicle (NOMV) vaccines prepared from mutants with attenuated endotoxin (lpxL1 knockout) and over-expressed sub-family B Factor H-binding proteins (FHbp). Animals were challenged intranasally two weeks after the third dose with wild-type strain H44/76, or were treated IP with anti-NOMV serum before and during the bacterial challenge. RESULTS: The NOMV-1 vaccine, prepared from the serogroup B H44/76 mutant, elicited ∼40-fold higher serum bactericidal antibody titers against the wild-type H44/76 challenge strain than the NOMV-2 vaccine prepared from a heterologous serogroup W mutant strain with different PorA and FHbp amino acid sequence variants. Compared to aluminum hydroxide-immunized control mice, the efficacy for prevention of any H44/76 colonization was 93% (95% confidence interval, 52-99, P<0.0001) for the NOMV-1 vaccine, and 19% (-3-36, P=0.23) for NOMV-2. NOMV-2-vaccinated mice had a 5.6-fold decrease in geometric mean CFU of bacteria per animal in tracheal washes compared to control mice (P=0.007). The efficacy of passive administration of serum from NOMV-1-vaccinated mice to immunologically naïve mice against colonization was 44% (17-61; P=0.002). CONCLUSIONS: Both NOMV vaccines protected against meningococcal colonization but there was greater protection by the NOMV-1 vaccine with antigens matched with the challenge strain. Meningococcal vaccines that target protein antigens have potential to decrease colonization.
BACKGROUND: The effect of protein-based meningococcal vaccines on prevention of nasopharyngeal colonization has been difficult to investigate experimentally because a reliable animal colonization model did not exist. METHODS:HumanCEACAM1transgenic mice, which can be colonized by meningococci, were immunized IP with one of two meningococcal native outer membrane vesicle (NOMV) vaccines prepared from mutants with attenuated endotoxin (lpxL1 knockout) and over-expressed sub-family B Factor H-binding proteins (FHbp). Animals were challenged intranasally two weeks after the third dose with wild-type strain H44/76, or were treated IP with anti-NOMV serum before and during the bacterial challenge. RESULTS: The NOMV-1 vaccine, prepared from the serogroup B H44/76 mutant, elicited ∼40-fold higher serum bactericidal antibody titers against the wild-type H44/76 challenge strain than the NOMV-2 vaccine prepared from a heterologous serogroup W mutant strain with different PorA and FHbp amino acid sequence variants. Compared to aluminum hydroxide-immunized control mice, the efficacy for prevention of any H44/76 colonization was 93% (95% confidence interval, 52-99, P<0.0001) for the NOMV-1 vaccine, and 19% (-3-36, P=0.23) for NOMV-2. NOMV-2-vaccinated mice had a 5.6-fold decrease in geometric mean CFU of bacteria per animal in tracheal washes compared to control mice (P=0.007). The efficacy of passive administration of serum from NOMV-1-vaccinated mice to immunologically naïve mice against colonization was 44% (17-61; P=0.002). CONCLUSIONS: Both NOMV vaccines protected against meningococcal colonization but there was greater protection by the NOMV-1 vaccine with antigens matched with the challenge strain. Meningococcal vaccines that target protein antigens have potential to decrease colonization.
Authors: Paul A Kristiansen; Fabien Diomandé; Absatou Ky Ba; Idrissa Sanou; Abdoul-Salam Ouédraogo; Rasmata Ouédraogo; Lassana Sangaré; Denis Kandolo; Flavien Aké; Inger Marie Saga; Thomas A Clark; Lara Misegades; Stacey W Martin; Jennifer Dolan Thomas; Sylvestre R Tiendrebeogo; Musa Hassan-King; Mamoudou H Djingarey; Nancy E Messonnier; Marie-Pierre Préziosi; F Marc Laforce; Dominique A Caugant Journal: Clin Infect Dis Date: 2012-10-19 Impact factor: 9.079
Authors: Oliver Koeberling; Anja Seubert; George Santos; Annalisa Colaprico; Mildred Ugozzoli; John Donnelly; Dan M Granoff Journal: Vaccine Date: 2011-05-13 Impact factor: 3.641
Authors: Peter T Beernink; Jutamas Shaughnessy; Emily M Braga; Qin Liu; Peter A Rice; Sanjay Ram; Dan M Granoff Journal: J Immunol Date: 2011-02-16 Impact factor: 5.422
Authors: Jamie Findlow; Ray Borrow; Matthew D Snape; Tom Dawson; Ann Holland; Tessa M John; Anita Evans; Karen L Telford; Ellen Ypma; Daniela Toneatto; Philipp Oster; Elizabeth Miller; Andrew J Pollard Journal: Clin Infect Dis Date: 2010-10-18 Impact factor: 9.079
Authors: Leah D Fletcher; Liesel Bernfield; Vicki Barniak; John E Farley; Alan Howell; Melissa Knauf; Peggy Ooi; Robert P Smith; Paige Weise; Mike Wetherell; Xiaoling Xie; Robert Zagursky; Ying Zhang; Gary W Zlotnick Journal: Infect Immun Date: 2004-04 Impact factor: 3.441
Authors: D M Daugla; J P Gami; K Gamougam; N Naibei; L Mbainadji; M Narbé; J Toralta; B Kodbesse; C Ngadoua; M E Coldiron; F Fermon; A-L Page; M H Djingarey; S Hugonnet; O B Harrison; L S Rebbetts; Y Tekletsion; E R Watkins; D Hill; D A Caugant; D Chandramohan; M Hassan-King; O Manigart; M Nascimento; A Woukeu; C Trotter; J M Stuart; McJ Maiden; B M Greenwood Journal: Lancet Date: 2013-09-12 Impact factor: 79.321
Authors: Arianna Marini; Omar Rossi; Maria Grazia Aruta; Francesca Micoli; Simona Rondini; Serafina Guadagnuolo; Isabel Delany; Ian R Henderson; Adam F Cunningham; Allan Saul; Calman A MacLennan; Oliver Koeberling Journal: PLoS One Date: 2017-07-25 Impact factor: 3.240
Authors: Isabelle Leduc; Kristie L Connolly; Afrin Begum; Knashka Underwood; Stephen Darnell; William M Shafer; Jacqueline T Balthazar; Andrew N Macintyre; Gregory D Sempowski; Joseph A Duncan; Marguerite B Little; Nazia Rahman; Eric C Garges; Ann E Jerse Journal: PLoS Pathog Date: 2020-12-08 Impact factor: 6.823